Aroldi Francesca, Prochilo Tiziana, Bonini Elena, Zaniboni Alberto
UO di Oncologia, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy.
Rev Recent Clin Trials. 2016;11(3):260-5. doi: 10.2174/1574887111666160226150650.
Currently, many novel therapies are available for physicians treating cancer; some of them are associated with adverse cardiac events. One of the most worrisome cardiac event is QT prolongation, which is a risk factor for developing the potentially fatal torsade de pointe. Many classes of drugs, both anticancer and concomitant agents, are involved in this issue. We report a review of old and new commonly used agents with torsadogenic potential.
目前，有许多新型疗法可供治疗癌症的医生使用；其中一些与不良心脏事件有关。最令人担忧的心脏事件之一是QT间期延长，这是发生潜在致命性尖端扭转型室速的一个危险因素。许多类药物，包括抗癌药和伴随用药，都与这个问题有关。我们报告了一篇关于具有致尖端扭转型室速潜力的新旧常用药物的综述。
